PiB-PET detects transthyretin-related cerebral amyloid angiopathy Transthyretin (TTR) is an amyloidogenic protein synthesized primarily (.95%) by the liver and, to a lesser extent, by the choroid plexuses and retinal pigment epithelium. Hereditary TTR amyloidosis (ATTR) is a multisystem disorder that may manifest with 3 main clinical phenotypes: familial amyloid polyneuropathy (FAP), familial amyloid cardiomyopathy, and familial leptomeningeal amyloidosis. 1 TTR-FAP is the most common presentation. More than 130 autosomal dominant mutations cause ATTR, with the Val30Met mutation being the most frequent variant worldwide: prevalence of up to 1:1,000 in endemic regions of Portugal, Sweden, and Japan. Highly penetrant endemic Val30Met-FAP occurs in early adulthood (before age 50) and manifests as a progressive motor-sensory neuropathy dominated by the involvement of small fibers and autonomic dysfunction. Untreated patients die 7-12 years from onset due to dysautonomia and cardiomyopathy. In nonendemic areas, Val30Met-TTR and other TTR variants have a later age at onset (after age 60), lower penetrance, greater phenotypical variability, and a 2-to 3-year gap from symptom onset to the definite diagnosis. TTR-familial leptomeningeal amyloidosis and cerebral amyloid angiopathy (CAA) are associated with selected TTR variants that deposit in the media and adventitia of medium-sized and small cerebral arteries and veins of the cortex and leptomeninges. Occasionally, ATTR-Val30Met may also lead to leptomeningeal amyloidosis throughout the natural course of the disease. 2 This CNS ATTR is mainly related to the production of TTR variants by the choroid plexus and manifests with TIA-like episodes, aura-like episodes, ischemic or hemorrhagic brain or spinal cord strokes, epileptic seizures, and dementia.
Since its introduction in 1990, liver transplantation has been the gold standard therapeutic option for TTR-FAP, with more than 2,000 patients having transplants to date. 3 Liver transplant inhibits the new synthesis of mutant TTR protein by the liver and rapidly reduces the total circulating mutant protein, but does not affect production by the choroid plexuses or retinal pigment epithelium. Although liver transplant appeared effective in stabilizing the progression of neuropathy, long-term retrospective surveys emphasized several limitations for such an invasive procedure.
Genotype and age at onset substantially influence survival rates after liver transplantation: in early-onset Val30Met patients, the prognosis was good (82% 5-year and 74% 10-year survival), whereas in lateonset Val30Met and non-val30Met patients, the prognosis did not differ from that of nontransplant patients (59% 5-year and 44% 10-year survival), primarily due to the progression of cardiac amyloidosis associated to continued deposition of wtTTR on existing deposits. 4 Thus, due to the limitations of LT, the development of novel modifying therapies is underway. Alternative therapies for TTR-FAP include the tetramer stabilizers (tafamidis and diflunisal) and new therapies aimed at posttranscriptional gene silencing such as small interfering RNAs and antisense oligonucleotides (currently in phase II or III development). 5 Concern over the long-term outcome of transplant patients was recently emphasized by a report documenting recurrent, sterotyped, transient focal neurologic episodes (TFNE) in 31% (27/87) of Val30Met-FAP patients who had received transplants. 6 TFNE manifested on average 14.6 years after the onset of the peripheral neuropathy and were pathologically correlated with CNS amyloidosis as suggested by examination of 7 brains. In this issue of Neurology ® , Sekijima et al. 7 confirmed that TTR leptomeningeal and CAA was indeed a complication of liver transplantation in ATTR-FAP and provide evidence that Pittsburgh compound B-PET (PiB-PET) can detect ATTR-CAA. The authors conducted a retrospective observational study on 53 patients (50 of whom carried the prototypical Val30Met mutation) who underwent partial (42 patients) or whole (11 patients) liver transplantation to treat early-onset (mean age at onset 34.5 years) TTR-FAP. TFNEs affected approximately 12% (6/53) of patients and manifested 14-21 years after the onset of TTR-FAP and 13.5 6 3.0 years after liver transplantation. Conventional structural imaging including CT, MRI, and CT or MRI angiography did not provide clear correlates (superficial siderosis, subarachnoid hemorrhages of convexity, cortical microbleeds) to the CNS symptoms/signs, leading the authors to hypothesize that TFNEs represent focal seizures or cortical spreading depression equivalents. More interestingly, PiB-PET was able to detect amyloid deposition in CNS in 11/15 examined posttransplant patients; independent of the presence (5 patients) or absence (6 patients) of CNS symptoms/signs, all positive cases had a duration of disease $10 years. To our knowledge, this is the first systematic study analyzing CNS-ATTR by any amyloid PET tracer. The pattern of PiB accumulation diverged from that observed in Alzheimer disease, and in b-amyloid CAA, since it was characterized by mild retention in the whole brain cortex, by an indistinct contrast between the cortex and white matter, and by an evident involvement of occipital and cerebellar regions. In one autopsied posttransplant patient, the pathologic counterpart of PiB accumulation was represented by amyloid deposition on leptomeningeal vessels of cerebrum, cerebellum, brainstem, and spinal cord, and, to a lesser extent, on superficial cortical layers arterioles: a typical pattern for TTR-CAA. By liquid chromatography-tandem mass spectrometry, the amyloid deposits were composed prevalently (.90%) of mutant TTR.
Thus, Sekijima and coworkers demonstrated that liver transplantation in TTR-FAP does not prevent the late progression of CNS amyloidosis due to ongoing synthesis of mutant TTR by choroid plexus, and is thus analogous to the posttransplant ocular amyloidosis related to the ongoing synthesis of mutant TTR by the retinal epithelium. 8 Intriguingly, the study suggests that PiB-PET may be more sensitive than conventional MRI in detecting symptomatic or asymptomatic TTR-CAA; this finding should be confirmed and extended in larger series of patients with early-and late-onset TTR-FAP associated with different genotypes, as well as in patients with primary TTR-familial leptomeningeal amyloidosis.
Knowledge of TTR-CAA as a possible late complication in TTR-FAP has obvious implications in the management of single patients (antiplatelet or anticoagulant therapies should be avoided in the presence of CAA), as well as in the development of future disease-modifying therapies, trials for which should consider brain TTR as an additional target.
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